PMID- 23704830
OWN - NLM
STAT- MEDLINE
DCOM- 20131231
LR  - 20221207
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 19
IP  - 19
DP  - 2013 May 21
TI  - Effect of Danzhijiangtang capsule on monocyte chemoattractant protein-1 mRNA 
      expression in newly diagnosed diabetes subclinical vascular lesions.
PG  - 2963-8
LID - 10.3748/wjg.v19.i19.2963 [doi]
AB  - AIM: To investigate the effect of Danzhijiangtang capsule (DJC) on monocyte 
      chemoattractant protein-1 (MCP-1) mRNA expression in newly diagnosed type 2 
      diabetes mellitus (T2DM) subclinical vascular lesions. METHODS: Sixty-two 
      patients with newly diagnosed T2DM subclinical vascular lesions were randomly 
      divided into a control group and treatment group of 31 cases each. Oral 
      antidiabetic therapy with routine western medicine was conducted in both groups, 
      and the treatment group was additionally treated with DJCs. The treatment course 
      for both groups was 12 wk. Before and after treatment, the total efficiency and 
      traditional Chinese medicine (TCM) syndrome score were calculated. The fasting 
      plasma glucose (FPG), 2-h plasma glucose (2hPG), fasting insulin (FINS), insulin 
      resistance index (IRI), hemoglobin (Hb)A1c, blood lipids, and hemorheology 
      indices were determined. In addition, the levels of vascular endothelial growth 
      factors including thrombomodulin (TM), von Willebrand factor (vWF), P-selectin 
      and MCP-1 mRNA were determined. RESULTS: After 12 wk of treatment, the TCM 
      syndrome score was significantly decreased compared to before treatment in both 
      groups. After treatment, FPG, 2hPG, HbA1c, FINS, IRI, total cholesterol, 
      triglycerides, low-density lipoprotein, high-density lipoprotein, whole blood low 
      shear specific viscosity, plasma specific viscosity, TM, vWF, P-selectin and 
      MCP-1 mRNA were significantly improved compared to before treatment in both 
      groups. After treatment, the total efficiency and TCM syndrome score in the 
      treatment group were better than in the control group. FINS, IRI, whole blood 
      high shear specific viscosity, plasma specific viscosity, TM, vWF, P-selectin and 
      MCP-1 mRNA level in the treatment group were significantly reduced after 
      treatment compared with control group. CONCLUSION: DJCs are efficacious in 
      supplementing qi, nourishing yin and invigorating blood circulation, and 
      upregulate MCP-1 mRNA expression in patients with T2DM subclinical vascular 
      lesions.
FAU - Fang, Zhao-Hui
AU  - Fang ZH
AD  - Department of Endocrinology, the First Affiliated Hospital of Anhui College of 
      Traditional Chinese Medicine, Hefei 230031, Anhui Province, China. 
      fangzhaohui@medmail.com
FAU - Liu, Yan
AU  - Liu Y
FAU - Bao, Tao-Tao
AU  - Bao TT
FAU - Ni, Ying-Qun
AU  - Ni YQ
FAU - Liu, Jian
AU  - Liu J
FAU - Shi, Guo-Bin
AU  - Shi GB
FAU - Wu, Ji-Ping
AU  - Wu JP
FAU - Yang, Jun-Ping
AU  - Yang JP
FAU - Zhang, Hong
AU  - Zhang H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Capsules)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (P-Selectin)
RN  - 0 (RNA, Messenger)
RN  - 0 (SELP protein, human)
RN  - 0 (THBD protein, human)
RN  - 0 (Thrombomodulin)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 0 (von Willebrand Factor)
SB  - IM
MH  - Administration, Oral
MH  - Biomarkers/blood
MH  - Blood Glucose/drug effects/metabolism
MH  - Capsules
MH  - Chemokine CCL2/*genetics
MH  - Chi-Square Distribution
MH  - China
MH  - Diabetes Mellitus, Type 2/blood/complications/diagnosis/*drug therapy/genetics
MH  - Diabetic Angiopathies/blood/diagnosis/*drug therapy/etiology/genetics
MH  - Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/*therapeutic use
MH  - Insulin/blood
MH  - Insulin Resistance
MH  - Male
MH  - Middle Aged
MH  - P-Selectin/blood
MH  - RNA, Messenger/*blood
MH  - Thrombomodulin/blood
MH  - Time Factors
MH  - Treatment Outcome
MH  - von Willebrand Factor/metabolism
PMC - PMC3660822
OTO - NOTNLM
OT  - Danzhijiangtang capsule
OT  - Monocyte chemoattractant protein-1
OT  - Subclinical vascular lesions
OT  - Type 2 diabetes mellitus
EDAT- 2013/05/25 06:00
MHDA- 2014/01/01 06:00
PMCR- 2013/05/21
CRDT- 2013/05/25 06:00
PHST- 2012/12/25 00:00 [received]
PHST- 2013/02/06 00:00 [revised]
PHST- 2013/02/28 00:00 [accepted]
PHST- 2013/05/25 06:00 [entrez]
PHST- 2013/05/25 06:00 [pubmed]
PHST- 2014/01/01 06:00 [medline]
PHST- 2013/05/21 00:00 [pmc-release]
AID - 10.3748/wjg.v19.i19.2963 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2013 May 21;19(19):2963-8. doi: 10.3748/wjg.v19.i19.2963.